More issues

Myths vs. Facts: Getting Juxtapid (lomitapide) Covered by Blue Cross Blue Shield in Michigan

Answer Box: Juxtapid Coverage with Blue Cross Blue Shield Michigan Myth: If your doctor prescribes Juxtapid, Blue Cross Blue Shield Michigan automatically covers it. Reality: Juxtapid requires prior authorization with strict documentation of homozygous familial hypercholesterolemia (HoFH), failure of first-line treatments, and REMS enrollment. Success depends on comprehensive clinical evidence,
5 min read

Myths vs. Facts: Getting Lumizyme (Alglucosidase Alfa) Covered by UnitedHealthcare in Illinois

Answer Box: Fastest Path to Lumizyme Coverage UnitedHealthcare requires prior authorization for Lumizyme (alglucosidase alfa) in Illinois. Approval depends on confirmed Pompe disease diagnosis (enzyme deficiency + genetic testing) and specialist prescriber involvement. The fastest path: submit PA through UnitedHealthcare provider portal with complete diagnostic documentation and weight-based dosing calculation. If
6 min read

How to Get Sylvant (siltuximab) Covered by Cigna in Pennsylvania: Complete Appeals Guide and Medical Necessity Requirements

Answer Box: Getting Cigna to Cover Sylvant (siltuximab) in Pennsylvania Eligibility: Cigna covers Sylvant for HIV-negative, HHV-8-negative idiopathic multicentric Castleman disease with prior authorization. Fastest path: Submit Cigna's Sylvant PA form with HIV/HHV-8 test results, pathology confirming multicentric Castleman disease, and specialist prescription. First step today: Call
6 min read

Blue Cross Blue Shield Texas Coverage Criteria for Voydeya (Danicopan): What Counts as "Medically Necessary"?

Answer Box: Getting Voydeya Covered by Blue Cross Blue Shield Texas Blue Cross Blue Shield of Texas (BCBSTX) requires prior authorization for Voydeya (danicopan) with specific medical necessity criteria: confirmed PNH diagnosis by flow cytometry, documented extravascular hemolysis on stable C5 inhibitor therapy (≥6 months), and completed vaccinations against encapsulated
5 min read